The Role of Pharmacokinetics in Preclinical Safety Studies of Synthetic Sex Steroids

  • Michael Humpel
  • B. Dusterberg
  • S. Beier
  • J. Schuppler
  • P. Gunzel
  • W. Elger
Part of the Reproductive Biology book series (PBTS)


Having in mind the necessity to contain the world’s population and the worldwide influence of U.S. safety requirements for sex steroids, every conference is of great interest in which scientists are given the opportunity to present their data to the regulatory body.


Rhesus Monkey Medroxyprogesterone Acetate Ethinyl Estradiol Cyproterone Acetate Human Dose 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Glocklin, VC: General considerations for studies of the metabolism of drugs and other chemicals. 65th Annual FASEB Meeting, Atlanta, April 16, 1981.Google Scholar
  2. 2.
    Benagiano, G, Fraser, I: The Depo-Provera debate. Commentary on the article “Depo-Provera, a critical analysis. ” Contraception, 24: 493, 1981.PubMedCrossRefGoogle Scholar
  3. 3.
    Dusterberg, B, Humpel, M, Speck, U: Terminal halflives in plasma and bioavailability of norethisterone, levonorgestrel, cyproterone acetate and gestodene in rats, beagles and rhesus monkeys. Contraception, 24: 673, 1981.PubMedCrossRefGoogle Scholar
  4. 4.
    Back, DJ, Breckenridge, AM, Crawford, FE, Orme, ML’E, Rowe, PH, Smith, E: First-pass effect of norethindrone in rabbits and rats. J Pharmacol Exp Ther, 207: 555, 1978.PubMedGoogle Scholar
  5. 5.
    Back, DJ, Breckenridge, AM, Crawford, FE, Mclver, M, Orme, ML’E, Rowe, PH, Smith, E: Kinetics of norethindrone in women. II. Single-dose kinetics. Clin Pharmacol Ther, 24: 448, 1978.PubMedGoogle Scholar
  6. 6.
    Becker, H, Dusterberg, B, Klosterhalfen, H: Bioverfugbarkeit von Cyproteronacetat nach oraler und intramuskularer applikation von Androcur™ bei mannern. Urologia Internationalis, 35: 381, 1980.PubMedCrossRefGoogle Scholar
  7. 7.
    Humpel, M, Wendt, H, Pommerenke, G, Weiss, C, Speck, U: Investigations of pharmacokinetics of levonorgestrel to specific consideration of a possible first-pass effect in women. Contraception, 17: 207, 1978.PubMedCrossRefGoogle Scholar
  8. 8.
    Humpel, M, Nieuweboer, B, Wendt, H, Speck, U: Investigations of pharmacokinetics of ethinyloestradiol to specific consideration of a possible first-pass effect. Contraception, 19: 421, 1979.PubMedCrossRefGoogle Scholar
  9. 9.
    Humpel, M: Unpublished results.Google Scholar
  10. 10.
    Back, DJ, Bates, MW, Breckenridge, AM, Crawford, FE, Orme, ML’E, Rowe, PH, Smiles, G, Smith, E: The metabolism of norethisterone and ethinyloestradiol by rat gut wall. J Steroid Biochem, 9: 823, 1978.CrossRefGoogle Scholar
  11. 11.
    Humpel, M: Pharmacokinetics and biotransformation of norethisterone in animals. A Review. Contraception, 26: 83, 1982.PubMedCrossRefGoogle Scholar
  12. 12.
    Sisenwine, SF, Kimmel, HB, Liu, AL, Ruelius, HW: The metabolic disposition of norgestrel in female rhesus monkeys. Drug Metab Disposition, 7: 1, 1979.Google Scholar
  13. 13.
    Helton, ED, Goldzieher, JW: The pharmacokinetics of ethynyl estrogens. A review. Contraception, 15: 255, 1977.PubMedCrossRefGoogle Scholar
  14. 14.
    Beier, S, Haase, F, Kosub, B, Dusterberg, B, Elger, W: The progestational activity of different gestagens used for human contraception in the beagle bitch. Contraception, 20: 533, 1979.PubMedCrossRefGoogle Scholar
  15. 15.
    Fitzgerald, J, de la Iglesia, F, Goldenthal, EI: Ten-year oral toxicity study with Norlestrin in rhesus monkeys. J Toxicol Environ Health, 10: 879, 1982.PubMedCrossRefGoogle Scholar
  16. 16.
    Humpel, M, Dusterberg, B: The role of pharmacokinetics in the development and use of long-acting progestogens. In: Benagiano, G, Zulli, E, Diczfalusy, E (Eds.): Progestogens in Therapy, New York, Raven Press, in press.Google Scholar
  17. 17.
    Grahame-Smith, DG: Preclinical toxicological testing and safeguards in clinical trials. Eur J Clin Pharmacol, 22: 1, 1982.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1986

Authors and Affiliations

  • Michael Humpel
    • 1
  • B. Dusterberg
    • 1
  • S. Beier
    • 1
  • J. Schuppler
    • 1
  • P. Gunzel
    • 1
  • W. Elger
    • 1
  1. 1.Schering AGBerlinWest Germany

Personalised recommendations